Otonomy names new CMO
This article was originally published in Scrip
Otonomy, a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for disorders of the inner and middle ear, has named Dr Dean Hakanson chief medical officer. Dr Hakanson has more than 16 years of industry experience in medical affairs, market access and health economic research with pharmaceutical companies including Novartis, Bristol-Myers Squibb, Genentech and GlaxoSmithKline. He joins Otonomy from Novartis, where he was most recently vice-president and head of health economics and outcomes research (HE&OR) for US medical and drug regulatory affairs.
You may also be interested in...
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.